The US Food & Drug Administration, using a cooperative agreement with the Robert J. Margolis, MD, Center for Health Policy at Duke University, is hosting a public virtual workshop to bring together key stakeholders, such as patients, biopharmaceutical companies, digital health technology (DHT) companies, clinicians, and academics, to understand the priorities for the development of DHTs for use in clinical trials. This meeting will explore the challenges and opportunities related to the use of DHTs in clinical trials during the drug development process, focusing on accelerometry and other sensor-based measurements. This event is open to all.